collection
MENU ▼
Read by QxMD icon Read
search

Mama

shared collection
52 papers 25 to 100 followers
By Alessandro Franciscon doctor
https://www.readbyqxmd.com/read/29208440/radiotherapy-in-the-setting-of-breast-reconstruction-types-techniques-and-timing
#1
REVIEW
Alice Y Ho, Zishuo I Hu, Babak J Mehrara, Edwin G Wilkins
As the use of breast reconstruction and postmastectomy radiotherapy (PMRT) has increased over the past decade, the typical approach to integrating radiotherapy with breast reconstruction has provoked intense controversy in the management of breast cancer. PMRT can lead to an increased frequency of complications in the reconstructed breast. Conversely, the reconstructed breast can increase the complexity of radiotherapy delivery. How to minimise the frequency of complications without compromising oncological or cosmetic outcomes of the reconstructed breast is an important shared multidisciplinary goal for oncologists and their patients...
December 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29254776/breast-cancer-biology-clinical-implications-for-breast-radiation-therapy
#2
REVIEW
Janet K Horton, Reshma Jagsi, Wendy A Woodward, Alice Ho
Historically, prognosis and treatment decision making for breast cancer patients have been dictated by the anatomic extent of tumor spread. However, in recent years, "breast cancer" has proven to be a collection of unique phenotypes with distinct prognoses, patterns of failure, and treatment responses. Recent advances in biologically based assays and targeted therapies designed to exploit these unique phenotypes have profoundly altered systemic therapy practice patterns and treatment outcomes. Data associating locoregional outcomes with tumor biology are emerging...
January 1, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29165285/hypofractionated-nodal-radiation-therapy-for-breast-cancer-was-not-associated-with-increased-patient-reported-arm-or-brachial-plexopathy-symptoms
#3
MULTICENTER STUDY
Nelson Leong, Pauline T Truong, Keith Tankel, Winkle Kwan, Lorna Weir, Ivo A Olivotto
PURPOSE: To determine whether nodal radiation therapy (RT) for breast cancer using modest hypofractionation (HF) with 2.25 to 2.5 Gy per fraction (fx) was associated with increased patient-reported arm symptoms, compared with conventional fractionation (CF) ≤2 Gy/fx. METHODS AND MATERIALS: Two cancer registries were used to identify subjects who received computed tomography-planned nodal RT for pT1-3, pN0-2, M0 breast cancer, from 2007 to 2010 at 2 cancer institutions...
December 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29153463/late-normal-tissue-effects-in-the-arm-and-shoulder-following-lymphatic-radiotherapy-results-from-the-uk-start-standardisation-of-breast-radiotherapy-trials
#4
Joanne S Haviland, Mariella Mannino, Clare Griffin, Nuria Porta, Mark Sydenham, Judith M Bliss, John R Yarnold
BACKGROUND AND PURPOSE: Adjuvant lymphatic radiotherapy (LNRT) is recommended for selected axillary node positive women with early breast cancer. We investigated whether hypofractionated LNRT is safe combined with similarly-hypofractionated breast/chest wall radiotherapy (RT). MATERIAL AND METHODS: The Standardisation of Breast Radiotherapy (START) pilot, A and B trials randomised women with early breast cancer to schedules of 2.67-3.3 Gy versus 2.0 Gy fractions (control)...
November 15, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28898379/effect-of-axillary-dissection-vs-no-axillary-dissection-on-10-year-overall-survival-among-women-with-invasive-breast-cancer-and-sentinel-node-metastasis-the-acosog-z0011-alliance-randomized-clinical-trial
#5
RANDOMIZED CONTROLLED TRIAL
Armando E Giuliano, Karla V Ballman, Linda McCall, Peter D Beitsch, Meghan B Brennan, Pond R Kelemen, David W Ollila, Nora M Hansen, Pat W Whitworth, Peter W Blumencranz, A Marilyn Leitch, Sukamal Saha, Kelly K Hunt, Monica Morrow
Importance: The results of the American College of Surgeons Oncology Group Z0011 (ACOSOG Z0011) trial were first reported in 2005 with a median follow-up of 6.3 years. Longer follow-up was necessary because the majority of the patients had estrogen receptor-positive tumors that may recur later in the disease course (the ACOSOG is now part of the Alliance for Clinical Trials in Oncology). Objective: To determine whether the 10-year overall survival of patients with sentinel lymph node metastases treated with breast-conserving therapy and sentinel lymph node dissection (SLND) alone without axillary lymph node dissection (ALND) is noninferior to that of women treated with axillary dissection...
September 12, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28943046/radical-radiation-therapy-for-oligometastatic-breast-cancer-results-of-a-prospective-phase-ii-trial
#6
Marco Trovo, Carlo Furlan, Jerry Polesel, Francesco Fiorica, Stefano Arcangeli, Niccolò Giaj-Levra, Filippo Alongi, Alessandro Del Conte, Loredana Militello, Elena Muraro, Debora Martorelli, Simon Spazzapan, Massimiliano Berretta
BACKGROUND AND PURPOSE: We conducted a prospective phase II multicentric trial to determine if radical radiation therapy to all metastatic sites might improve the progression-free survival (PFS) in oligometastatic breast cancer patients. Secondary endpoints were local control (LC), overall survival (OS) and toxicity. METHODS AND MATERIALS: Inclusion criteria were the following: oligometastatic breast cancer with ≤5 metastatic sites, FDG-PET/CT staging, no brain metastases, primary tumor controlled...
September 21, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28822332/eso-esmo-3rd-international-consensus-guidelines-for-breast-cancer-in-young-women-bcy3
#7
Shani Paluch-Shimon, Olivia Pagani, Ann H Partridge, Omalkhair Abulkhair, Maria-João Cardoso, Rebecca Alexandra Dent, Karen Gelmon, Oreste Gentilini, Nadia Harbeck, Anita Margulies, Dror Meirow, Giancarlo Pruneri, Elzbieta Senkus, Tanja Spanic, Medha Sutliff, Luzia Travado, Fedro Peccatori, Fatima Cardoso
The 3rd International Consensus Conference for Breast Cancer in Young Women (BCY3) took place in November 2016, in Lugano, Switzerland organized by the European School of Oncology (ESO) and the European Society of Medical Oncologists (ESMO). Consensus recommendations for the management of breast cancer in young women were updated from BCY2 with incorporation of new evidence to inform the guidelines, and areas of research priorities were identified. This manuscript summarizes the ESO-ESMO international consensus recommendations, which are also endorsed by the European Society of Breast Specialists (EUSOMA)...
October 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28391871/tamoxifen-with-radiotherapy-compared-with-tamoxifen-alone-in-elderly-women-with-early-stage-breast-cancer-treated-with-breast-conserving-surgery-a-systematic-review-and-meta-analysis
#8
REVIEW
Tyler R Chesney, Jennifer Xin Yin, Nikoo Rajaee, Andrea C Tricco, Anthony W Fyles, Sergio A Acuna, Adena S Scheer
BACKGROUND: Our aim was to assess the effect of adjuvant radiotherapy on recurrence and survival for elderly women (≥70) with early-stage hormone receptor-positive breast cancer treated with breast conserving surgery (BCS) and Tamoxifen. MATERIALS AND METHODS: MEDLINE, EMBASE, and Evidence-Based Medicine Reviews were systematically searched through August 12, 2016 for randomized controlled trials (RCTs) comparing radiotherapy to no radiotherapy and presenting outcomes for women ≥70years...
April 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28382401/management-of-the-positive-axilla-in-2017
#9
EDITORIAL
Eli Avisar, Tolga Ozmen
No abstract text is available yet for this article.
June 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/23032615/predictors-of-locoregional-recurrence-after-neoadjuvant-chemotherapy-results-from-combined-analysis-of-national-surgical-adjuvant-breast-and-bowel-project-b-18-and-b-27
#10
Eleftherios P Mamounas, Stewart J Anderson, James J Dignam, Harry D Bear, Thomas B Julian, Charles E Geyer, Alphonse Taghian, D Lawrence Wickerham, Norman Wolmark
PURPOSE: The limited information on predictors of locoregional recurrence (LRR) after neoadjuvant chemotherapy (NC) has resulted in controversy about the optimal use of adjuvant radiotherapy and the timing of sentinel lymph node biopsy. PATIENTS AND METHODS: We examined patterns and predictors of LRR as first event in combined analysis of two National Surgical Adjuvant Breast and Bowel Project (NSABP) neoadjuvant trials. NC was either doxorubicin/cyclophosphamide (AC) alone or AC followed by neoadjuvant/adjuvant docetaxel...
November 10, 2012: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/11773149/predictors-of-local-regional-recurrence-after-neoadjuvant-chemotherapy-and-mastectomy-without-radiation
#11
Thomas A Buchholz, Susan L Tucker, Lawrence Masullo, Henry M Kuerer, Jessica Erwin, Jessica Salas, Debbie Frye, Eric A Strom, Marsha D McNeese, George Perkins, Angela Katz, S Eva Singletary, Kelly K Hunt, Aman U Buzdar, Gabriel N Hortobagyi
PURPOSE: To define clinical and pathologic predictors of local-regional recurrence (LRR) for patients treated with neoadjuvant chemotherapy and mastectomy without radiation. PATIENTS AND METHODS: We analyzed the outcome of the 150 breast cancer cases treated on prospective institutional trials with neoadjuvant chemotherapy and mastectomy without postmastectomy radiation. Clinical stage at diagnosis was I in 1%, II in 43%, IIIA in 23%, IIIB in 25%, and IV in 7%. No patient had inflammatory breast cancer...
January 1, 2002: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/10924981/is-radiation-alone-adequate-treatment-to-the-axilla-for-patients-with-limited-axillary-surgery-implications-for-treatment-after-a-positive-sentinel-node-biopsy
#12
S Galper, A Recht, B Silver, M V Bernardo, R Gelman, J Wong, S J Schnitt, J L Connolly, J R Harris
PURPOSE: To estimate the possible efficacy of axillary radiation therapy (AXRT) following a positive sentinel node biopsy (SNB), we evaluated the risk of regional nodal failure (RNF) for patients with clinical Stage I or II, clinically node-negative invasive breast cancer treated with either no dissection or a limited dissection (LD) defined as removal of 5 nodes or less followed by AXRT. MATERIALS AND METHODS: From 1978 to 1987, 292 patients underwent AXRT in the absence of axillary dissection; 126 underwent AXRT following LD...
August 1, 2000: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/23690420/lumpectomy-plus-tamoxifen-with-or-without-irradiation-in-women-age-70-years-or-older-with-early-breast-cancer-long-term-follow-up-of-calgb-9343
#13
RANDOMIZED CONTROLLED TRIAL
Kevin S Hughes, Lauren A Schnaper, Jennifer R Bellon, Constance T Cirrincione, Donald A Berry, Beryl McCormick, Hyman B Muss, Barbara L Smith, Clifford A Hudis, Eric P Winer, William C Wood
PURPOSE: To determine whether there is a benefit to adjuvant radiation therapy after breast-conserving surgery and tamoxifen in women age ≥ 70 years with early-stage breast cancer. PATIENTS AND METHODS: Between July 1994 and February 1999, 636 women (age ≥ 70 years) who had clinical stage I (T1N0M0 according to TNM classification) estrogen receptor (ER) -positive breast carcinoma treated by lumpectomy were randomly assigned to receive tamoxifen plus radiation therapy (TamRT; 317 women) or tamoxifen alone (Tam; 319 women)...
July 1, 2013: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/21900114/age-breast-cancer-subtype-approximation-and-local-recurrence-after-breast-conserving-therapy
#14
Nils D Arvold, Alphonse G Taghian, Andrzej Niemierko, Rita F Abi Raad, Meera Sreedhara, Paul L Nguyen, Jennifer R Bellon, Julia S Wong, Barbara L Smith, Jay R Harris
PURPOSE: Prior results of breast-conserving therapy (BCT) have shown substantial rates of local recurrence (LR) in young patients with breast cancer (BC). PATIENTS AND METHODS: We studied 1,434 consecutive patients with invasive BC who received BCT from December 1997 to July 2006. Ninety-one percent received adjuvant systemic therapy; no patients received trastuzumab. Five BC subtypes were approximated: estrogen receptor (ER) or progesterone receptor (PR) positive, HER2 negative, and grades 1 to 2 (ie, luminal A); ER positive or PR positive, HER2 negative, and grade 3 (ie, luminal B); ER or PR positive, and HER2 positive (ie, luminal HER2); ER negative, PR negative, and HER2 positive (ie, HER2); and ER negative, PR negative, and HER2 negative (ie, triple negative)...
October 10, 2011: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27919884/3rd-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-3
#15
F Cardoso, A Costa, E Senkus, M Aapro, F André, C H Barrios, J Bergh, G Bhattacharyya, L Biganzoli, M J Cardoso, L Carey, D Corneliussen-James, G Curigliano, V Dieras, N El Saghir, A Eniu, L Fallowfield, D Fenech, P Francis, K Gelmon, A Gennari, N Harbeck, C Hudis, B Kaufman, I Krop, M Mayer, H Meijer, S Mertz, S Ohno, O Pagani, E Papadopoulos, F Peccatori, F Pernault-Llorca, M J Piccart, J Y Pierga, H Rugo, L Shockney, G Sledge, S Swain, C Thomssen, A Tutt, D Vorobiof, B Xu, L Norton, E Winer
No abstract text is available yet for this article.
December 5, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27646947/postmastectomy-radiotherapy-an-american-society-of-clinical-oncology-american-society-for-radiation-oncology-and-society-of-surgical-oncology-focused-guideline-update
#16
REVIEW
Abram Recht, Elizabeth A Comen, Richard E Fine, Gini F Fleming, Patricia H Hardenbergh, Alice Y Ho, Clifford A Hudis, E Shelley Hwang, Jeffrey J Kirshner, Monica Morrow, Kilian E Salerno, George W Sledge, Lawrence J Solin, Patricia A Spears, Timothy J Whelan, Mark R Somerfield, Stephen B Edge
Purpose A joint American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology panel convened to develop a focused update of the American Society of Clinical Oncology guideline concerning use of postmastectomy radiotherapy (PMRT). Methods A recent systematic literature review by Cancer Care Ontario provided the primary evidentiary basis. The joint panel also reviewed targeted literature searches to identify new, potentially practice-changing data. Recommendations The panel unanimously agreed that available evidence shows that PMRT reduces the risks of locoregional failure (LRF), any recurrence, and breast cancer mortality for patients with T1-2 breast cancer with one to three positive axillary nodes...
December 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/21852010/adjuvant-chemotherapy-and-radiotherapy-in-triple-negative-breast-carcinoma-a-prospective-randomized-controlled-multi-center-trial
#17
RANDOMIZED CONTROLLED TRIAL
Jianhua Wang, Mei Shi, Rui Ling, Yuesheng Xia, Shanquan Luo, Xuehai Fu, Feng Xiao, Jianping Li, Xiaoli Long, Jianguo Wang, Zengxia Hou, Yunxia Chen, Bin Zhou, Man Xu
BACKGROUND AND PURPOSE: Triple-negative breast cancer (TNBC) presents a high risk breast cancer that lacks the benefit from hormone treatment, chemotherapy is the main strategy even though it exists in poor prognosis. Use of adjuvant radiation therapy, which significantly decreases breast cancer mortality, has not been well described among poor TNBC women. The aim of this study was to evaluate whether the combination of chemotherapy and radiotherapy could significantly increase survival outcomes in TNBC women after mastectomy...
August 2011: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/15850919/patient-subsets-with-t1-t2-node-negative-breast-cancer-at-high-locoregional-recurrence-risk-after-mastectomy
#18
Pauline T Truong, Mary Lesperance, Aydin Culhaci, Hosam A Kader, Caroline H Speers, Ivo A Olivotto
PURPOSE: To identify patient subsets with T1-T2N0 breast cancer at high risk of locoregional recurrence (LRR) who may warrant consideration for postmastectomy radiotherapy. METHODS AND MATERIALS: Data were analyzed for 1505 women referred between 1989 and 1999 with pathologic T1-T2N0M0 breast cancer treated with mastectomy with clear margins and no adjuvant radiotherapy. Logistic regression analysis was performed to identify statistically significant factors associated with LRR...
May 1, 2005: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/17577015/impact-of-a-higher-radiation-dose-on-local-control-and-survival-in-breast-conserving-therapy-of-early-breast-cancer-10-year-results-of-the-randomized-boost-versus-no-boost-eortc-22881-10882-trial
#19
RANDOMIZED CONTROLLED TRIAL
Harry Bartelink, Jean-Claude Horiot, Philip M Poortmans, Henk Struikmans, Walter Van den Bogaert, Alain Fourquet, Jos J Jager, Willem J Hoogenraad, S Bing Oei, Carla C Wárlám-Rodenhuis, Marianne Pierart, Laurence Collette
PURPOSE: To investigate the long-term impact of a boost radiation dose of 16 Gy on local control, fibrosis, and overall survival for patients with stage I and II breast cancer who underwent breast-conserving therapy. PATIENTS AND METHODS: A total of 5,318 patients with microscopically complete excision followed by whole-breast irradiation of 50 Gy were randomly assigned to receive either a boost dose of 16 Gy (2,661 patients) or no boost dose (2,657 patients), with a median follow-up of 10...
August 1, 2007: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/21134654/intensity-modulated-radiation-therapy-for-breast-is-it-for-everyone
#20
REVIEW
Beryl McCormick, Margie Hunt
Intensity-modulated radiation therapy (IMRT) became available to the radiation oncology community in the late 1990s, and its initial applications were to increase conformality of dose to the target, allowing for both dose escalation and decreased radiation to adjacent normal organs. In most disease sites, these continue to be the goals of IMRT. However, for breast cancer, IMRT has emerged with a different endpoint, namely improving dose homogeneity throughout the targeted breast. In 2 recent prospective randomized trials comparing IMRT with "standard" planning, IMRT was associated with a significant decrease in both acute side effects and late fibrosis, which was related directly to dose homogeneity...
January 2011: Seminars in Radiation Oncology
label_collection
label_collection
3610
1
2
2016-04-07 12:07:51
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"